archive-edu.com » EDU » M » MUSC.EDU

Total: 320

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Hollings Cancer Center - Medical University of South Carolina
    Carolina s premier cancer research and treatment center featured clinical Trials Learn more about clinical trials at Hollings Cancer Center here Patient Cancer Information Treatment programs by cancer type and patient support resources Research Hollings Cancer Center is the state s only National Cancer Institute designated center Across the State See what Hollings Cancer Center is accomplishing with partners across the state Giving Find out how to support the mission

    Original URL path: http://hcc.musc.edu/index.htm (2015-11-11)
    Open archived version from archive


  • MUSC Hollings Cancer Center | About Us
    It is the state s only National Cancer Institute NCI designated cancer center and one of fewer than 70 in the U S Founded in 1993 and named for former US Senator and South Carolina Governor Ernest Fritz Hollings the cancer center serves a culturally and socio economically diverse state whose populations experience unique and urgent disparities in cancer incidence and mortality As the state s foremost cancer treatment and research center Hollings Cancer Center unites more than 200 experts in treatment research education prevention and control and outreach to address South Carolina s significant cancer problem The Center s resources extend throughout South Carolina via partnerships with other healthcare organizations ensuring that all patients in the state have access to our innovative and compassionate care Patients are at the center of everything Hollings Cancer Center does For the 27 000 South Carolinians who will be diagnosed with cancer this year the Hollings Cancer Center is leading the way in changing what is possible in cancer care Mission The mission of the Hollings Cancer Center is to reduce the cancer burden in South Carolina through the highest quality care innovative research outstanding professional education and statewide cancer prevention programs with

    Original URL path: http://hcc.musc.edu/about/ (2015-11-11)
    Open archived version from archive

  • MUSC Hollings Cancer Center | Clinical Trials
    Clinical Trials Clinical Trials Every drug that has ever made a difference in cancer treatment was once a part of a clinical trial The Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future Ask your doctor if a clinical trial is right for you Print This Page HOLLINGS HOME About Hollings Patient Cancer Information Clinical Trials Search for

    Original URL path: http://hcc.musc.edu/clinicaltrials/ (2015-11-11)
    Open archived version from archive

  • MUSC Hollings Cancer Center | News
    with faculty experts assist you with arranging interviews video and photo shoots on campus or help you locate photos press releases and recent news items All requests should be directed to Allison Leggett Director of Strategic Communications Allison Leggett Phone 843 792 0376 E mail leggett musc edu After Hours Requests Media requests made after hours on weekends and on holidays should be directed to the PR person on call

    Original URL path: http://hcc.musc.edu/news/ (2015-11-11)
    Open archived version from archive

  • MUSC Hollings Cancer Center | Contact Us
    Form If are a new patient and would like to schedule an appointment you may call our Health Connection line at 843 792 1414 If you are outside the Charleston Area you may call Health Connection toll free at 1 800 424 MUSC Established Patient Appointments If you need to schedule an appointment call the Hollings directly at 843 792 9300 Physician Referral Information Call MEDULINE at 843 792 2200 or 1 800 922 5250 24 hours a day seven days a week Mailing Address Medical University of South Carolina Hollings Cancer Center Attn Department or Individual s Name 86 Jonathan Lucas Street P O Box 250955 Charleston SC 29425 Please include the department or individual in the address Where to Find Us Maps Directions to Facilities Parking Options Clinical Administration Patient Care E mail Contact Form Phone 843 792 9300 Clinical Trials Contact Susan Shannon E mail shannsu musc edu Phone 843 792 9321 Search Clinical Trials at Hollings Cancer Center Public Relations Contact Allison Leggett E mail leggett musc edu Phone 843 792 0376 More on Public Relations at Hollings Cancer Center Academic Administration Research Education E mail Contact Form Phone 843 792 6659 More on Administrative Leadership

    Original URL path: http://hcc.musc.edu/contact/ (2015-11-11)
    Open archived version from archive

  • Second Summit of Cervical Cancer Free South Carolina
    Cervical Cancer Free South Carolina summit January 7 8 2016 Hyatt Regency Greenville Greenville South Carolina Signature Sponsors Cervical Cancer Free South Carolina Hollings Cancer Center Thursday January 7 2016 12 6 PM Registration Ongoing through Conference Pre Conference Workshop 1 2 45 PM 1A HPV 101 What You Need to Know about HPV Reviewing current knowledge and data on HPV cervical cancer and the HPV vaccine 1B HPV 201 Reducing HPV associated Disease through Vaccination HPV vaccine and state of the art strategies to increase vaccination 2 45 3 PM Break Opening Session 3 4 PM Cervical Cancer in SC Improved Health through Education Innovation Matt Prisby Founder Cheryl Sirisky Prisby Endowed Scholarship Fund Heather Brandt PhD Co Founder Co Chair Cervical Cancer Free South Carolina Jennifer Young Pierce MD MPH Co Founder Co Chair Cervical Cancer Free South Carolina 4 5 30 PM Film Screening Someone You Love The HPV Epidemic 5 30 6 PM Keynote Speaker Tamika Felder National Cervical Cancer Spokeswoman Founder of Tamika Friends and Cervivor Patient Advocacy Groups 6 7 30 PM Opening Reception and Poster Session Friday January 8 2016 8 8 30 AM Registration Continental Breakfast Session 2 Preference Indicated by Registrant 8 30 10 AM 2A Research Basic and Clinical Science Progress 2B Cancer related Health Disparities in Rural Communities 2C Vaccinating Adolescents Success Opportunities 2D Advocating for Policies to Support Cervical Cancer Prevention Control 10 10 15 AM Break Session 3 Preference Indicated by Registrant 10 15 11 45 AM 3A Vaccination Research 3B Cervical Cancer Prevention Control in the 21st Century 3C Improving HPV Vaccination through Partnerships Alternate Settings Pharmacies 3D Survivorship 11 45 12 PM Break Closing Session Working Lunch 12 1 30 PM Jennifer S Smith PhD MPH Director Cervical Cancer Free Coalition 1 30 1 45

    Original URL path: http://hcc.musc.edu/research/conferences/CervicalCancerFreeSC/index.htm (2015-11-11)
    Open archived version from archive

  • Immunotherapy Researcher Awarded $6.8 Million Grant
    to him earning such an impactful and prestigious grant and we are confident his work will lead to more breakthroughs in understanding and combatting cancer The grant focuses on the heat shock protein HSP grp94 a molecule that is highly expressed in cancer cells and whose drug like inhibitors have been identified by the researchers on this project The collaborative team is working to learn more about grp94 uncover its cancer specific roles and refine its targeted inhibitors for eventual clinical development of new cancer therapies This multi project initiative brings together cancer researchers from multiple disciplines across the three institutions Li s group has played a leading role in demonstrating that grp94 is a master regulator for toll like receptors TLRs integrins low density lipoprotein receptor related protein 5 LRP5 and glycoprotein a repetitions predominant GARP It is believed that these molecules drive cancer development Targeting grp94 will allow the researchers to shut down these molecules and thus be effective against cancer Li who holds the Sally Abney Rose Endowed Chair in Stem Cell Biology Therapy SmartState Center of Economic Excellence at MUSC was recruited to MUSC as the Hollings Cancer Center s cancer immunology program leader in 2010 His long term primary research involves the study of how cancer escapes recognition by the immune system His research team has made seminal contributions to understanding the immunological properties of HSPs in cancer immunotherapy and immune tolerance providing critical genetic evidence linking the HSPs to adaptive immunity and pioneering the use of HSP complexes for immunotherapy in human leukemias Li has been the leader of four investigator initiated Investigational New Drug applications in heat shock proteins vaccination platforms to treat cancer Alberg added Throughout his career Dr Li has demonstrated boundless energy extraordinary work ethic and significant success in his

    Original URL path: http://hcc.musc.edu/news/pressreleases/2015/Li%20P01%209.22.15 (2015-11-11)
    Open archived version from archive

  • Genetic Clues In Ovarian Cancer Identified
    research has Ovarian cancer is the fourth leading cause of cancer in American women and seventh most common cancer in women throughout the world World Health Organization In 2015 more than 14 000 American women will die of ovarian cancer according to the American Cancer Society Most ovarian cancers have low survival rates typically because of the misunderstanding of symptoms and discovery of the cancer in later less treatable stages Although MOCs are a less common type of ovarian cancer with generally good prognosis when diagnosed in early stages they are twice as likely to be resistant to treatment at later stages said Andrew Berchuck M D director of gynecologic oncology at Duke University Cancer Institute and senior author of the study Our results will contribute to the identification of women at greatest risk of developing the disease with the long term goal of prevention The association analysis was based on 1 644 women diagnosed with MOC and more than 21 000 women without ovarian cancer The research was conducted as part of the Collaborative Oncological Gene environment Study COGS launched in 2009 with the goal of determining risks of breast ovarian and prostate cancer A major strength of this study is the large number of women with MOCs which was made possible by pooling data contributed by investigators from over 40 international studies of ovarian cancer within the Ovarian Cancer Association Consortium said Linda Kelemen Sc D associate professor and researcher at the Hollings Cancer Center at the Medical University of South Carolina and co first author By using a genome wide scan we could identify genetic variants that were significantly more common in women with MOC compared to those without ovarian cancer Co first author Kate Lawrenson Ph D of Keck Medicine of USC believes the research will lead the way to the development of risk prediction strategies followed by clinical interventions with the potential to prevent ovarian cancer altogether rather than treating the disease once it has already taken hold The five year survival rates for ovarian cancer have not changed much in the past 30 years and is partly from viewing ovarian cancer as a single disease she said Our results shed light on differences in genetic risk factors for the different ovarian cancers such as MOCs I m hanging my hopes on prevention My bet is that prevention approaches will be better than finding a cure for a disease that is often diagnosed late The study Genome wide significant risk associations for mucinous ovarian carcinoma was published online in Nature Genetics on June 15 2015 Also contributing to the study was Paul D P Pharoah University of Cambridge Funding for the study comes from the European Commission s Seventh Framework Programme grant the Ovarian Cancer Association Consortium the U S National Cancer Institute GAME ON Post GWAS initiative and numerous grants from funders including the American Cancer Society the Canadian Institutes of Health Research and other cancer societies and organizations throughout the world Kelemen L

    Original URL path: http://hcc.musc.edu/news/pressreleases/2015/Kelemen%20Ovarian%20Study (2015-11-11)
    Open archived version from archive



  •